Congenital defects/diseases Background:
Background
Mycophenolate mofetil (MMF; CellCept ® ) is one of the most commonly prescribed immunosuppressant drugs used to prevent organ transplant rejection [1] . In the United States, 89.9% of de novo renal transplant recipients are prescribed MMF or other mycophenolic acid derivatives, making it the most used immunosuppressant in these patients [2] . MMF inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH), which plays an important role in the de novo synthesis of purines, and intercepts the proliferation of B and T lymphocytes [3] . Mycophenolic acid derivatives have a different toxicity profile compared to calcineurin inhibitors and other antiproliferative agents [4] . Gastrointestinal tract disturbances are the most commonly reported adverse effects of MMF, with afebrile diarrhea being the most commonly reported manifestation, with an incidence rate of 12-40% in renal transplant patients [5] . However, the use of MMF for pregnant women has a great risk of miscarriage and fetal development defects such as external ear malformation, ocular malformation, cleft lip and palate, and abnormality of distal limbs, heart, esophagus or kidneys [6] [7] [8] [9] [10] . The National Transplantation Pregnancy Registry (NTPR) revealed a 45% miscarriage rate of 33 pregnancies that were reported by 24 patients receiving mycophenolate treatment, and 4-5% congenital defects rate compared to 3% in the general population of the United States [11] . In 2007, MMF was reclassified by the US Food and Drug Administration from class C to class D in response to studies that reported miscarriages and teratogenic effects of MMF products and metabolites [12] . In June 2012, the US FDA added a boxed warning (BW) to the prescribing information of all mycophenolic acid derivatives, describing their potential to cause increased risks of first trimester pregnancy loss and congenital malformations. th week of pregnancy) and the mother was on dual immunosuppression with slight elevation of liver function test, which was managed by increasing tacrolimus dose, aiming for a level of 10 ug/L. At 37 weeks, an obstetric ultrasound was done, which showed a cephalic presentation fetus with abdominal circumference of 35.4 cm (75 th centile), a head circumference in the 95 th centile, and an estimated fetal weight of 3.827 kg. The fetus scored 8 out of 8 in a biophysical profile and had polyhydramnios with 20 cm of amniotic fluid and an enlarged stomach. A lower-segment C-section was performed at 38 weeks due to failure to progress with full dilatation. The newborn was a male who had a tracheoesophageal fistula with esophageal atresia and a bilateral ear canal atresia (Microtia) with normal sensorineural conduction, with no other congenital abnormalities. Thoracoscopic ligation of fistula and thoracotomy with esophageal repair was performed and a bone anchored hearing aid for conductive hearing loss was implanted. Figure 1 shows plain abdominal and chest X-ray of the newborn diagnostic of esophageal atresia and Figure 2 shows a contrast study after the repair.
Case Report

Discussion
Mycophenolic acid derivatives have been associated with a specific pattern of congenital anomalies that include microtia, cleft lip and palate, external auditory canal atresia, ocular anomalies, diaphragmatic hernia, and congenital heart defects [9] [10] [11] [12] [13] [14] . Esophageal atresia associated with prenatal exposure to mycophenolic acid has been described in 9 patients who also had other associated malformations. Hoeltzenbein et al., Schonar et al., and Parisi et al. reported cases of several congenital malformations in which mothers were receiving mycophenolate therapy, among other medications [14] [15] [16] [17] . Martin et al. reported 4 cases of esophageal atresia; 2 of these cases matched the proposed embryopathy phenotype (cleft palate and lip, external auditory canal atresia, congenital heart defects, and microtia) [18] . The other 2 cases presented with esophageal atresia with other milder manifestations; one with patent foramen ovale and mild facial anomalies, and the other patient was diagnosed with congenital dorsal hemivertebra. The patients did not show any association between the periods of prenatal exposure to mycophenolic acid and the reported congenital anomalies [13, 14] .
In our case, the fetus was exposed to MMF until the 20 th week of pregnancy. In 2007, Roche Laboratories, Inc. issued a drug warning indicating that MMF use during pregnancy is associated with increased pregnancy loss and congenital malformation, especially external ear and facial malformations, as well as anomalies of distal limbs, heart, esophagus, and kidneys. Based on the post-marketing data and the US National Transplantation Pregnancy Registry, the US FDA changed the MMF pregnancy category from C to D [12] . Since steroids and tacrolimus are not known to cause this pattern of anomalies, the most likely cause is MMF teratogenicity. Our patient had 2 uneventful pregnancies after discontinuation of MMF, while still on steroids, tacrolimus, and lamivudine.
Conclusions
The use of mycophenolic acid derivatives during pregnancy is associated with increased risk of esophageal atresia and microtia. Its use should be avoided in women of reproductive age who are pregnant or planning to get pregnant. Counseling patients about its risk and the importance of contraception and pregnancy planning should be emphasized.
